Aileron Therapeutics Statistics
Share Statistics
Aileron Therapeutics has 21.67M shares outstanding. The number of shares has increased by 343.45% in one year.
| Shares Outstanding | 21.67M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.35% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 19.54M |
| Failed to Deliver (FTD) Shares | 22.29K |
| FTD / Avg. Volume | 24.94% |
Short Selling Information
The latest short interest is 233.27K, so 1.08% of the outstanding shares have been sold short.
| Short Interest | 233.27K |
| Short % of Shares Out | 1.08% |
| Short % of Float | 1.19% |
| Short Ratio (days to cover) | 3.47 |
Valuation Ratios
The PE ratio is -0.89 and the forward PE ratio is -2.15.
| PE Ratio | -0.89 |
| Forward PE | -2.15 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 2.04 |
| P/FCF Ratio | -0.71 |
| PEG Ratio | n/a |
Enterprise Valuation
Aileron Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 4.17, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.17 |
| Quick Ratio | 4.17 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.69 |
| Cash Flow / Debt | -412.67 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.28% and return on capital (ROIC) is -234.69%.
| Return on Equity (ROE) | -2.28% |
| Return on Assets (ROA) | -0.15% |
| Return on Capital (ROIC) | -234.69% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.05M |
| Employee Count | 15 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -40% in the last 52 weeks. The beta is 2.34, so Aileron Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.34 |
| 52-Week Price Change | -40% |
| 50-Day Moving Average | 3.22 |
| 200-Day Moving Average | 3.57 |
| Relative Strength Index (RSI) | 36.4 |
| Average Volume (20 Days) | 89.36K |
Income Statement
In the last 12 months, Aileron Therapeutics had revenue of $0 and earned -$15.73M in profits. Earnings per share was $-3.42.
| Revenue | 0 |
| Gross Profit | -119.00K |
| Operating Income | -16.28M |
| Net Income | -15.73M |
| EBITDA | -15.61M |
| EBIT | - |
| Earnings Per Share (EPS) | -3.42 |
Balance Sheet
The company has $17.31M in cash and $48.00K in debt, giving a net cash position of $17.27M.
| Cash & Cash Equivalents | 17.31M |
| Total Debt | 48.00K |
| Net Cash | 17.27M |
| Retained Earnings | -288.52M |
| Total Assets | 104.22M |
| Working Capital | 13.03M |
Cash Flow
In the last 12 months, operating cash flow was -$19.81M and capital expenditures $0, giving a free cash flow of -$19.81M.
| Operating Cash Flow | -19.81M |
| Capital Expenditures | 0 |
| Free Cash Flow | -19.81M |
| FCF Per Share | -4.31 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ALRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -150% |
| FCF Yield | -40.1% |
Analyst Forecast
The average price target for ALRN is $19, which is 733.3% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19 |
| Price Target Difference | 733.3% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Nov 11, 2022. It was a backward split with a ratio of 1:20.
| Last Split Date | Nov 11, 2022 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -4.47 |
| Piotroski F-Score | 2 |